MTPA to Commercialize ALS Therapy Exservan in the US

MTPA to Commercialize ALS Therapy Exservan in the US

284131

MTPA to Commercialize ALS Therapy Exservan in the US

Mitsubishi Tanabe Pharma America (MTPA) has entered an agreement with Aquestive Therapeutics to market Exservan, an oral film formulation of riluzole, for treating amyotrophic lateral sclerosis (ALS) in the United States. Under terms of the agreement, Aquestive — the developer of Exservan — will be the exclusive manufacturer and supplier of the product and will receive an upfront payment, specified milestone payments, as well as royalties on the therapy’s net sales in the U.S. MTPA, which also is…

You must be logged in to read/download the full post.